



THE AD HOC GROUP FOR MEDICAL RESEARCH

January 23, 2025

The Honorable Mike Johnson
Speaker of the House
U.S. House of Representatives
Washington, DC 20515

The Honorable John Thune
Majority Leader
U.S. Senate
Washington, DC 20510

The Honorable Hakeem Jeffries
Minority Leader
U.S. House of Representatives
Washington, DC 20515

The Honorable Chuck Schumer
Minority Leader
U.S. Senate
Washington, DC 20510

Dear Speaker Johnson, Majority Leader Thune, Minority Leader Jeffries, and Minority Leader Schumer:

On behalf of over 400 organizations representing, patients, clinicians, scientists, educators, academic and research institutions, and industry in the Ad Hoc Group for Medical Research, I write to urge you to act with urgency to reach agreement on top line discretionary funding levels for FY 2025 with a commitment to nondefense spending that allows maximum investment in the National Institutes of Health (NIH).

Our community strongly supports an approach to the final FY 2025 spending package that finalizes funding levels in advance of the March expiration of the current continuing resolution (CR). In November 2024, [over 400 organizations across the NIH stakeholder community recommended](#) at least the Senate Appropriations Committee-approved level of \$48.9 billion for NIH in a final FY 2025 spending package. While CRs serve an important function in keeping the federal government open, they also regrettably create inefficiencies and add uncertainty to government operations. Without clarity on appropriations, federal agencies, including NIH, are left in budget limbo. Avoiding further delays in finalizing funding for the current fiscal year will enable our nation's medical research enterprise to be maximally efficient and strategic in addressing myriad health needs.

As you know, NIH-supported research in nearly every congressional district nationwide is one of the country's greatest assets combatting debilitating health challenges that affect patients, families, and communities from city centers to rural frontiers. To maximize the opportunities that medical research provides to improve health – from potential preventative breakthroughs to new and more promising strategies in treating cancer, Alzheimer's, mental health disorders, and other devastating diagnoses – we must continue predictable, robust growth in NIH investment. Such a commitment not only will ensure the country continues to advance new cures and other medical interventions, it also will develop the next generation of medical researchers, spur local and regional economic growth, accelerate our global competitiveness, reinforce national security, and help deliver positive health outcomes to patients, families, and communities nationwide.

The first step to achieving those goals, however, is establishing an overall discretionary spending level that allows appropriate investment in medical research. We strongly urge you to work swiftly in securing bipartisan, bicameral agreement on topline discretionary spending allocations and to continue Congress's longstanding, bipartisan tradition of ensuring that any final FY 2025 spending agreement reflects a strong commitment to medical research.

Sincerely,

A handwritten signature in black ink, appearing to read 'Tannaz Rasouli'.

Tannaz Rasouli
Executive Director

cc: The Honorable Tom Cole
The Honorable Susan Collins
The Honorable Rosa DeLauro
The Honorable Patty Murray